FALLS CHURCH, Va., Oct. 31 /PRNewswire/ -- The industry's foremost authorities on clinical research will lead Clinical Trials: Effective Recruitment and Informed Consent Strategies, a 2 day workshop in Philadelphia, PA (http://www.fdanews.com/informedconsent), sponsored by the RxTrials Institute and FDAnews. This interactive workshop focuses on how to speed the IRB and FDA review processes, shorten trial cycles and get products to market faster. For more information on the workshop, call toll free (888) 838-5578, +1 (703) 538-7600 or visit http://www.fdanews.com/informedconsent. Failure to recruit subjects is the number one reason clinical trials do not meet deadlines. Compounded by failure to properly consent patients, 72 percent of all trials run over schedule by more than one month and only 6 percent are completed on time. Delayed or canceled studies and negative publicity can cost companies millions - even billions - of dollars. This hands-on session will address ways to avoid the industry's biggest pitfalls. Workshop faculty who will lead this event include: Christine Pierre, RN, President and CEO, RxTrials, Inc. Mark Hochhauser, Ph.D., Consultant, Member of the Institutional Review Board, North Memorial Health Care Clint Hermes, Partner, Ropes & Gray LLP Linda Strause, Ph.D., Executive Director, Oncology Clinical Operations, Vical Inc. RxTrials Institute, the foremost expert on clinical research site management, marketing, and business development, is pleased to present a comprehensive series of training programs for the clinical research team. RxTrials Institute is known nationwide for groundbreaking presentations and customized training programs that are both innovative and dynamic. FDAnews is the premier provider of domestic and international regulatory, legislative and business news and information for executives in industries regulated by the U.S. Food and Drug Administration. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books, special reports and conferences to stay in compliance with international standards and FDA's complex and ever-changing regulations to get their products to market faster and boost profits.